Randomized, Two-treatment, Two-sequence, Four-period, Full-replicate Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects
Condition: Ulcerative Colitis Intervention: Drug: Apriso 0.375G Extended-Release Capsule Sponsor: Valeant Pharmaceuticals International, Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2017 Category: Research Source Type: clinical trials
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Condition: Colorectal Cancer Interventions: Drug: Mesalamine 2400 MG; Drug: Mesalamine 1200 MG; Other: Placebo Sponsors: Christoph Gasche; Prof. Dr. Gabriela Möslein, Germany; Prof. Dr. Hans Vasen, The Netherlands; Prof. Dr. med. Jan Lubinski, Poland; Prof. Dr. med. Yaron Niv, Israel; Univ. Prof. Dr. Judith Karner-Hanusch, Austria; Ann-Sofie Backman, MD PhD, Sweden Not yet recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2017 Category: Research Source Type: clinical trials
